With a recent resurgence in interest in VM26, further studies are warranted to determine precisely how VE-cadherin signalling regulates VM in SCLC and how VE-cadherin signalling could be exploited as a therapeutic target in this most recalcitrant cancer. This evidence concerns the gene CDH5 and small cell lung carcinoma.